What do systematic reviews say?

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

Serious adverse events (including mortality) · adults with asthma

Withdrawals due to adverse events · men with sexual dysfunction

Adverse event: lead failure/ displacement · adults with chronic pain

Proportion of children with adverse events · children with nocturnal enuresis

Proportion of children with adverse events · children with nocturnal enuresis

Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease

Adverse events: hysteroscopy complications · women with submucous fibroids and otherwise unexplained subfertility

Adverse events: hysteroscopy complications · subfertile women with endometrial polyps diagnosed by ultrasonography prior to treatment with gonadotropin and intrauterine insemination

Treatment‐related adverse events Depression · adults (aged 16 years and over) with CF

Non‐serious adverse events for all placebos · patients with mental health disorders

Withdrawals due to adverse events · Patients with shoulder pain

Adverse events: Clinically important change · Adolescents with psychosis

Adverse events: Clinically important effect · Adolescents with psychosis

Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males

Overall local/injection site adverse events · 9‐ to 15‐year‐old females

Adverse events: paraesthesia ‐ not reported · patients undergoing lumbar punctures with traumatic needles (Quincke, Greene, Hingson Ferguson, Lutz, Brace, Rovenstine, Lemmon)